Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Off to the races
November 2019
SHARING OPTIONS:

BEDFORD, Mass.—Late October saw the launch of Verseau Therapeutics Inc., which hit the ground running with $50 million in financing from 20/20 HealthCare Partners, 3SBio, Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua Capital. The company's aim will be to develop novel, first-in-class immunotherapies that modulate macrophages, with the startup funding to help move its macrophage checkpoint modulator programs into the clinic. Verseau has a strategic collaboration in place with 3SBio, under which the latter gains an exclusive license to develop and commercialize a number of MCM antibodies for all human oncology indications in Greater China, including mainland China, Taiwan, Hong Kong and Macau. Verseau will retain all global rights.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.